Recent Quotes (30 days)

You have no recent quotes
chg | %

Neurokine Pharmaceuticals Inc  

(Public, OTCMKTS:NEUKF)   Watch this stock  
Find more results for OTC:NEUKF
0.0000 (0.00%)
Jan 29 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.04
Open     -
Vol / Avg. 0.00/879.00
Mkt cap 578,840.00
P/E     -
Div/yield     -
EPS 0.00
Shares 115.77M
Beta -1.79
Inst. own     -

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -6931.72% -
Return on average equity - -
CDP Score - -


1275 6th Ave W
+1-604-8057783 (Phone)
+1-604-2250588 (Fax)

Website links


Neurokine Pharmaceuticals Inc. is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. Its research and development activities are focused on assessing known drugs and compounds, developing hypotheses concerning their usage for new indications (diseases), and conducting experimentation and clinical research to test those hypotheses. As of March 12, 2012, the Company had identified three anti-inflammatory products, which included NK001, NK002 and NK-003. NK-001 is an application of the generic drug Etanercept for treating neurocognitive impairment in Coronary Artery Bypass Graft (CABG) surgery patients. NK-002 is a development-stage drug for the treatment of Alzheimer´┐Żs disease.